Healthcare Industry News: CryoLife
News Release - August 4, 2008
CryoLife Announces Management Promotions
ATLANTA, Aug. 4 (HSMN NewsFeed) -- CryoLife, Inc. (NYSE: CRY ), a biomaterials, medical device and tissue processing company, announced today that Bruce G. Anderson has been promoted to vice president of U.S. sales and marketing, and that Richard C. Gridley has been promoted to vice president of international sales and marketing. Both men will report to Gerald B. Seery, senior vice president of worldwide sales and marketing. Additionally, the company has announced the promotion of Timothy M. Neja to vice president of laboratory operations. Mr. Neja will report to D. Ashley Lee, executive vice president, chief operating officer and chief financial officer.Mr. Gridley, 37, will now manage sales and marketing in Canada, Asia- Pacific, and Central and South America. Mr. Gridley joined CryoLife in 2005 as marketing manager for BioGlue® Surgical Adhesive and most recently served as marketing manager, global bioadhesives. Previously, Mr. Gridley was with Global Link Logistics, Inc., Rusch Inc. and 3M Company.
Mr. Neja, 42, has most recently served as senior director of laboratory operations at CryoLife. In his new role, he will continue to be responsible for all laboratory operations, including tissue processing and BioGlue manufacturing, as well as purchasing and facilities management. Prior to joining CryoLife in 1997 as production manager, Mr. Neja was with Centeon.
"We are pleased to announce these well-deserved promotions within our management team," said Steven G. Anderson, CryoLife president and chief executive officer. "Bruce, Rich and Tim have each made substantial contributions to the success of the organization over the past several years, and we believe they will continue to enhance our ability to bring cutting-edge solutions to cardiac and vascular surgeons world-wide."
About CryoLife, Inc.
Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The Company recently received FDA clearance for the CryoValve® SG pulmonary human heart valve, processed using CryoLife's proprietary SynerGraft® Technology. The Company's BioGlue® Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. CryoLife distributes Hemostase MPH®, a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the United Kingdom and Germany for cardiac, vascular, and general surgery, subject to certain exclusions. The Company also distributes the CryoLife-O'Brien® stentless porcine heart valve, which is CE marked for distribution within the European Community.
For additional information about the company, visit CryoLife's Web site: http://www.CryoLife.com
Source: CryoLife
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
